DSIP

DSIP is a nonapeptide originally isolated from rabbit sleep-inducing brain extracts. It has been studied for effects on sleep architecture and stress response. Evidence for efficacy is limited and mixed. It may act through modulation of GABA and opioid systems.

PubMed results: 346 · Human studies: 88 · Animal studies: 324

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

Doses studied in published research. Information presented for research purposes only, not a recommendation for human use.

• Subcutaneous — standard range 100-300 mcg, Once before bed

7-8 minutes (low confidence)

• Sleep architecture research (Limited): DSIP (delta sleep-inducing peptide) was originally isolated from sleep-related brain extracts and has been studied for effects on sleep patterns and sleep architecture, though human efficacy evidence is mixed and limited
• Stress-response modulation research (Limited): Research literature has examined DSIP in relation to stress response and adaptive endocrine changes, with heterogeneous findings across experimental models
• GABA and opioid system interaction hypotheses (Theoretical): Mechanistic discussions propose that DSIP may act in part through modulation of GABAergic and opioid-related pathways, though precise receptor pharmacology remains incompletely defined

• Daytime drowsiness or altered sleep timing (research observations) — Mild, Not established. Given research interest in sleep modulation, sedation-related effects are theoretically plausible, but published human side-effect rates are not well established
• No robust documented human adverse profile — Mild, Not established. Formal clinical safety datasets for DSIP remain limited relative to approved pharmaceuticals, and many historical studies are small or methodologically mixed

• Concurrent sedative or CNS-depressant research contexts (Theoretical / Preclinical): Hypothesized effects on sleep and GABA-related systems raise theoretical additive CNS depression concerns when studied alongside other sedating agents
• Insufficient modern clinical safety data (Theoretical / Preclinical): Mixed efficacy evidence and limited contemporary controlled trials mean contraindications are not firmly established beyond general peptide research cautions

Lyophilized (powder): Refrigerated (2-8°C), Up to 24 months. Light sensitive: yes, store dark

Reconstituted (solution): Refrigerated (2-8°C), 4-6 weeks. Solvent: Bacteriostatic water